| Autor: |
null Saliaj, BCCCP BCPS PharmD Matthew Li, null Rizzo, null Nassar, null Nso, Zarwa Idrees, Luis A. Medina, Anastasia Novikov, Salim Yaghi, Francisco J. Cuevas, null Salafia, BCPS PharmD Hamid Razaki, Charles Berman, Issac Sachmechi, Theo Trandafirescu, Debra Brennessel, George T. Martin, Jazila Mantis |
| Rok vydání: |
2021 |
| Popis: |
Aims This study aimed to investigate the potential of tocilizumab therapy in minimizing mortality and mechanical ventilation (MV) requirements among hospitalized COVID-19 patients.Methods A single-center, retrospective, observational cohort study of 375 patients with severe COVID-19 (March 1 and April 22, 2020) included 150 patients treated with Tocilizumab and 225 consecutive control patients adjusted for age and gender. Both groups received concomitant standard of care treatments in addition to Tocilizumab. The statistical methods relied on survival analyses, conditional logistic regression models, and contingency analyses. The primary outcomes included in-hospital mortality and the MV requirement.Results Tocilizumab associated with improved in-hospital mortality (34.7% vs 46.7%, P = 0.0136) and lower requirement for MV on days 1, 3, and 5 after treatment (P = 0.005, P Conclusion Our study demonstrates a significant reduction in mortality and decreased requirement of MV with tocilizumab treatment in addition to the standard of care. Early administration of Tocilizumab within 48 hours reduces the risk of mortality. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
